Cardiff Oncology, Inc.

Contributing Author

Recent Articles by Cardiff Oncology, Inc.

Jun-02	Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting CRDF GlobeNewswire
Jun-01	Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference CRDF -22.11% GlobeNewswire
May-21	Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC CRDF GlobeNewswire
May-14	Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update CRDF GlobeNewswire
Apr-28	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CRDF GlobeNewswire
Apr-27	Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity CRDF GlobeNewswire
Apr-21	Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 CRDF -7.30% GlobeNewswire
Apr-17	Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting CRDF +6.51% GlobeNewswire
Apr-09	Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth CRDF +7.05% CRDF -5.39% GlobeNewswire
Mar-20	Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer CRDF GlobeNewswire
Mar-19	Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting CRDF GlobeNewswire
Feb-26	Cardiff Oncology to Participate in Three Upcoming Investor Conferences CRDF GlobeNewswire
Feb-24	Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update CRDF +12.35% CRDF +8.97% GlobeNewswire
Feb-19	Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference CRDF GlobeNewswire
Jan-27	Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC CRDF -31.97% GlobeNewswire
Jan-27	Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development CRDF -31.97% GlobeNewswire
Dec-08	Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 CRDF +10.90% GlobeNewswire
Dec-08	Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference CRDF +10.90% GlobeNewswire
Nov-24	Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference CRDF GlobeNewswire
Nov-06	Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update CRDF GlobeNewswire
Nov-04	Cardiff Oncology to Participate in Two Upcoming Investor Conferences CRDF GlobeNewswire
Oct-02	Cardiff Oncology to Participate in Two Upcoming Investor Conferences CRDF GlobeNewswire
Aug-28	Cardiff Oncology to Participate in Three Upcoming Investor Conferences CRDF GlobeNewswire
Jul-29	Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) CRDF -24.77% CRDF -11.26% GlobeNewswire
Jul-29	Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update CRDF -24.77% CRDF -11.26% GlobeNewswire
Jun-17	Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC CRDF -18.38% CRDF GlobeNewswire
Jun-02	Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 CRDF GlobeNewswire
May-08	Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update CRDF +5.62% GlobeNewswire

Cardiff Oncology, Inc.

Recent Articles by Cardiff Oncology, Inc.

Upgrade your Finviz experience